We considered several key issues regarding the development of a DNA-based human immunodeficiency virus type 1 (HIV-1) vaccine: (1) should the candidate vaccine construct be derived from incident or prevalent HIV-1 strains; and (2) should circulating plasma virus, archived HIV-1 provirus recovered from peripheral blood mononuclear cells, or both be included? To address these questions, we collected circulating HIV-1 strains from infected individuals residing in Abidjan, Côte d'Ivoire. From a panel of 23 strains, 22 were HIV-1 subtype A in gag, 19 of which phylogenetically clustered with the recombinant HIV-1, CRF02-AG strains from West Africa. The mosaic genome of CRF02-AG was confirmed by sequencing the protease gene. A consensus gag p24 protein sequence was generated and 147 of 148 codons were identical to CRF02-AG (IbNG). Regardless of the sequence origin (RNA, provirus, incident, or prevalent), the gag p24 consensus sequences were highly representative of these distinct virologic compartments. These data suggest that the consensus sequence generated from incident and prevalent infections may provide an appropriate sequence for a DNA vaccine and is largely representative of the major circulating viral strain.
INTRODUCTION
Although many HIV-1 candidate vaccines have advanced in development, a vaccine that is effective against HIV-1 transmission remains urgently needed as an estimated 40 million people of the world's population may be infected (Moore, 2002) . While prevention (sterilizing immunity) of HIV-1 infection still seems remote, effective vaccination may potentially prevent transmission and slow disease progression. Knowledge of the predominant HIV-1 subtype, sub-subtypes, and circulating recombinant forms (CRF) in a targeted population may be critical to determining whether potential vaccines should include a single strain, a recombinant circulating form, or a cocktail of antigens from different HIV-1 strains. The importance of matching a vaccine candidate to local circulating strains is unclear but evidence suggests that cytotoxic T-lymphocyte cross-reactivity among different HIV-1 subtypes will be an important component of a single efficacious HIV vaccine (Cao et al., 1997; Ferrari et al., 1997; Buseyne et al., 1998; McAdam et al., 1998; Rowland-Jones et al., 1999) . HIV-1 infection is more prevalent and genetically complex in Africa than anywhere else in the world. Therefore, characterization of the HIV-1 population is essential to our goal of developing an effective HIV vaccine for West Africa.
There is the danger of designing a vaccine based on a unique isolate rather than the predominant circulating strain. Obtaining comprehensive data on the pool of circulating strains is critical for designing vaccines based on local strains. For example, in Thailand, the initial epidemic within injecting drug users (IDU) was largely HIV-1 subtype B; a 1994 cross-section study (Wasi et al., 1995) found that 80% of prevalent infections were subtype B and 20% were subtype E. However, a 1995-1998 prospective cohort study found that 80% of incident infections were subtype E (Subbarao et al., 2000; Van-1 Presented in part at the 1 st Annual International Conference on HIV and Immunotherapies, Palm Beach, FL, June 28-July 1, 2000 (Abstract No. 63 ). This study was carried out under an approved protocol in accordance with guidelines set forth by the Centers for Disease Control and Prevention.
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HIV-1 has been genotypically divided into three distinctive groups: M, N, and O. Group M (for Major) comprises most of the HIV-1 strains that cause AIDS worldwide and has been further subdivided into 9 different subtypes (A-D, F-H, J, and K) (Janssens et al., 1997; Carr et al., 1998b) . Many mosaic or subtype recombinant forms of HIV-1 have also been described and are believed to represent about 10% of all circulating HIV-1 strains (Gao et al., 1998; McCutchan et al., 1996; Robertson et al., 1997; Robertson et al., 1995a,b) . In some regions of the world, HIV-1 recombinant strains, now designated as circulating recombinant forms (Robertson et al., 2000) , have established a high prevalence; they are as common as the local subtypes and may play a major role in the AIDS pandemic (Carr et al., 1998b) . For instance, in Senegal, Cameroon, Gabon, and Nigeria, 50-85% of circulating strains are a recombinant form of HIV-1 derived from subtypes A and G, called CRF02-AG . Other examples of inter-subtype recombinants that have relative substantial prevalence include the A/E strain in southeast Asia designated CRF01-AE Gao et al., 1996) , subtype B/C recombinants in China designated CRF07-BC (Su et al., 2000) and CRF08-BC (Piyasirisilp et al., 2000) , and a subtype A/B form in Russia's IDU population termed CRF03-AB (Bobkov et al., 1998; Liitsola et al., 1998) . The presence of the subtype A/G recombinant form, CRF02-AG, throughout West and Central Africa Carr et al., 1998a; Nkengasong et al., 2000; Andersson et al., 1999; McCutchan et al., 1999; Peeters et al., 2000; Toure-Kane et al., 2000) has major implications for vaccine development in this region of high HIV-1 prevalence.
In this study, we sought to determine the best HIV-1 vaccine candidate for a targeted West African population. We compared viral sequences derived from incident and prevalent cases of HIV-1 infection and derived a consensus sequence that clearly represents both circulating plasma virus and cellular provirus. Furthermore, this comparative analysis indicates that the best HIV-1 vaccine candidate for Abidjan, Côte d'Ivoire, and perhaps other areas of West Africa, is closely related to the major inter-subtype recombinant virus, CRF02-AG predominant in this region.
RESULTS
We conducted a detailed biologic description and characterization of HIV-1 recovered from 23 HIV-infected persons in Abidjan, Côte d'Ivoire, 4 of whom were incident cases (Table 1 ). The p24 region of gag was sequenced from all strains, and sequence information was obtained from either the circulating plasma virus (n ϭ 14) or DNA provirus (n ϭ 9). All 23 sequences along with reference sequences, including 7 circulating-recombinant form CRF02-AG strains from West and Central Africa, were used to construct a phylogenetic tree (Fig.  1) . HIV-1 subtype A represented the vast majority of the specimens, accounting for 22 (95.7%) of the 23 sequences. One specimen (IC1435) clustered with subtype B and D reference strains. The 22 subtype A strains and the derived Abidjan consensus sequence clustered together, but two distinct secondary branches of subtype A grouping were observed. Of the 22 subtype A strains, 19 clustered with the 7 CRF02-AG strains and the Abidjan consensus sequence, while 3 appeared distinct and clustered more closely with prototypic full-length subtype A strains. The branch structure supporting the distinct clustering within the subtype A grouping has a bootstrap value of 83; the strains from Abidjan repeatedly remained clustered, as shown in Fig. 1 . Moreover, the tree topology was similar whether neighbor-joining, neighbor-joining with bootstrapping, or maximum-likelihood methodologies were used (data not shown). Pairwise gag p24 
a FSW, female sex worker; ARV, persons starting antiretroviral therapy; TB, tuberculosis patient.
b Source of nucleic acid for sequence analysis. c Twenty-two gag p24 specimens were HIV-1 subtype A, but 19 specimens (denoted by A/G) cluster with A/G reference strains; n/a, inadequate sequence available for analysis.
nucleotide sequence divergence among all 22 Abidjan subtype A isolates ranged from 1.7 to 11.4%. Excluding 1 distinct strain (IC763) that clustered with a CRF02-AG reference strain from the analysis reduced the pairwise gag p24 nucleotide sequence divergence range from 1.7 to 6.7%. The sequence divergence among the 3 strains in the other secondary subtype A branch was 2.2 to 5.9%.
The protease region of the pol gene was sequenced in 16 of 23 specimens to confirm the presence of intersubtype recombinant HIV sequences and potential CRF02-AG strains. Seven specimens yielded inadequate sequence for analysis of the pol region. All 16 sequences along with Group M reference subtypes including CRF from West Africa were used to construct a phylogenetic tree (Fig. 2) . By phylogenetic analysis, 14 of 16 sequences were determined to be subtype G in protease, similar to CRF02-AG strains and indicative of an A/G recombinant strain. The 14 protease subtype G strains from Abidjan clustered together with the 6 CRF02-AG reference strains; this branch structure has bootstrap support of 83%. Pairwise protease sequence divergence among all the Abidjan protease subtype G isolates ranged from 0.7 to 11.9%. Two of the 16 specimens (IC1739 and IC1435) did not cluster with subtype G in protease analysis. Specimen IC1739 clustered with subtype B reference strains, suggesting an A/B recombinant strain. Specimen IC1435 clustered with subtype B and D reference strains in the pol protease region, identical to the findings in the gag p24 region.
Prior to translation of the 23 DNA sequences, all gagderived sequences were aligned, generating an Abidjan consensus nucleotide sequence. The Abidjan consensus nucleotide sequence was 99% identical to the intersubtype recombinant CRF02-AG and only one nonsynonymous nucleotide substitution was observed (data not shown). Table 2 summarizes their homology to the Abidjan consensus nucleotide sequence. The homology range for the 22 subtype A strains was 93.4-99.2% with a mean of 96.9%. The single nonsubtype A strain (IC1435) was less homologous (91.5%) to the consensus sequence. The 4 incident and 19 prevalent strains were found to be 97.1 and 96.6% homologous to Abidjan consensus sequence, respectively. DNA homology for the 14 circulating plasma virus and 9 provirus sequences was very similar, 96.6 and 96.8%, respectively. The overall homology to the prototype A/G recombinant CRF02-AG (IbNG) sequence for all 23 DNA sequences was 96.6%.
All 23 gag p24 sequences were translated and aligned. A consensus protein-coding sequence (Abidjan sequence) comprising 148 amino acids was subsequently derived (Fig. 3) . Virtually all of the codons (147 of 148) in the Abidjan sequence were identical to the intersubtype recombinant strain, CRF02-AG. At codon position 7, a Gly-to-Ala alteration was observed between the Abidjan sequence and the CRF02-AG reference sequence. All 23 Ivorian sequences were Ala at this position due to a single nucleotide difference (G-to-C change) in the second position of the codon. Minor codon variations among the 23 strains as compared to the reference CRF02-AG were observed throughout the translated sequence, but percentage variability at each position in the Abidjan consensus sequence was limited (Fig. 4) . There was complete homology at approximately 80% of the codons in all 23 sequences, and there were less than two changes per codon in 90% of the Abidjan consensus sequence. Furthermore, 3 or more individual strains differed at any one particular amino acid in less than 10% of the codon positions. To compare sequence similarities between incident and prevalent strains, gag consensus sequences were generated for isolates from each group. The incident strain consensus coding sequence was based on the 4 incident specimens (IC098, IC200, IC896, and IC928), and the prevalent strain consensus sequence was generated using the 19 prevalent strains (Fig. 3) . Surprisingly, both the incident and prevalent strain consensus sequences were identical to each other and to the Abidjan consensus sequence. Two of the 4 incident strains were 99% identical to the Abidjan consensus sequence, and the other 2 strains showed either three or five changes along the entire 148-amino-acid sequence (Fig. 5a) . Six of 19 prevalent strains were 99% identical to the Abidjan sequence, and the remaining prevalent strain sequences were at least 95% identical (Fig. 5a) .
Fourteen gag p24 sequences derived from circulating plasma virus were translated and aligned to generate a consensus sequence. When compared, complete homology between the circulating virus consensus sequence and the Abidjan consensus sequence was observed. Alignment of the translated sequences showed limited strain-to-strain variability; 10 of 14 sequences had five or fewer changes among the 148 codons (Fig. 5b) . A proviral DNA-derived (9 strains) consensus sequence was also generated. Again, complete homology to the Abidjan consensus sequence and limited strain-to-strain variability was observed (Fig. 5b) . When the circulating virus and proviral DNA-derived consensus sequences were compared, they were identical to each other.
DISCUSSION
Several key issues regarding an HIV-1 DNA vaccine candidate for West Africa remain unresolved. We considered whether the candidate virus should be recovered from incident strains or the most prevalent HIV-1 strain, and whether circulating plasma virus, archived HIV-1 provirus recovered from PBMCs, or both should be included.
In this report, we describe the first detailed analysis of the current population of circulating prevalent and incident HIV-1 strains in Abidjan and propose our most likely vaccine candidate for this region of West Africa. HIV-1 subtype A was previously shown to be the predominant strain (95%) circulating within Abidjan, Côte d'Ivoire (Ellenberger et al., 1999) , and the interior of this West African country (Nkengasong et al., 2000) . Based on partial env sequencing, this subtype A virus was shown to be phylogenetically distinct from other subtype A strains observed in East Africa (Ellenberger et al., 1999) . A recent report has extended this initial description to indicate that the majority of strains from Côte d'Ivoire were recombinant A/G, CRF02-AG . We recently completed a similar phylogenetic analysis of the same subtype A viral strains circulating within Abidjan while including the inter-subtype recombinant virus CRF02-AG and found that they cluster together (data not shown). Therefore, in our initial analysis of strains from this region of Africa, many were classified as subtype A (Howard et al., 1994; Howard and Rasheed, 1996) rather than recombinants because CRF02-AG is a complex mosaic virus with alternating A and G sequences in which both gag and env derive largely from subtype A.
Our current sample set of 23 specimens from Côte d'Ivoire was examined in both the gag and pol regions of the HIV genome to further confirm any recombinant forms. In this analysis, greater than 95% of the specimens were shown to be subtype A in the gag region, and 19 of 22 specimens clustered distinctly with CRF02-AG strains. The protease region of pol in CRF02-AG is subtype G, and 87.5% of the strains in this study set are subtype G, consistent with the inter-subtype recombinant and CRF02-AG-mosaic structure. The CRF02-AG prevalence estimate for the relatively small sample size is 78% and despite an error of prevalence greater than 10%, our estimate is within the 50-85% range for CRF02-AG recombinants observed in West Africa . A systematic selection bias with respect to subtype appears unlikely since the samples were independently collected at three clinics without known dates of infection. Furthermore, the lack of significant clustering by clinic or period in the phylogenetic analyses suggests that infections are being transmitted in a broad, heterogeneous manner in Abidjan. Our data confirm the geographic dispersion of CRF02-AG in Côte d'Ivoire and its continuing transmission within Abidjan, as evidenced by our finding that all 4 incident HIV-1 strains were intersubtype recombinant A/G virus.
In earlier studies, investigators have reported a number of recombinant or mosaic HIV-1 genomes worldwide, including some form of recombination by eight subtypes of HIV-1 group M. In this study, we have identified two recombinant patterns in our limited sampling in Abidjan, including A/G and A/B (strain ICE1739). Based on the discordant subtype results between partial gag and pol sequences, greater than 90% of the 23 strains in our study are recombinant viruses. This percentage exceeds the global estimations on circulating recombinant viruses as well as the overall percentages of 51 to 75% shown in other areas of West and West Central Africa (Montovan et al., 2000) . Surveillance for HIV genetic subtypes is important for vaccine development and is essential for refining diagnostic and treatment strategies. The introduction of antiretroviral treatment in parts of Africa, ultimately to include protease inhibitors, raises concerns because HIV-1 subtype G virus has decreased susceptibility to protease inhibitors (Descamps et al., 1998) . Importantly, the complex mosaic CRF02-AG virus is subtype G in the protease gene.
Of course, the central issue for vaccine development remains determining how much the diversity of HIV sequences affects immune recognition of the encoded proteins and, consequently, whether vaccines based on one strain will protect against others. Investigators have shown significant cytotoxic T-lymphocyte cross-reactivity for different HIV subtypes (Cao et al., 1997; Ferrari et al., 1997; Buseyne et al., 1998; McAdam et al., 1998; Rowland-Jones et al., 1999) ; thus a vaccine based on a single subtype or circulating recombinant form may be broadly applicable. Although the correlates of immune protection in HIV-1 infection are unknown, matching the local strain may maximize the chance of success for a candidate vaccine. In other regions of the world, a consensus sequence based on circulating prevalent strains may indeed differ from a sequence derived from incident strains. Furthermore, a consensus sequence derived from archived provirus may ultimately differ from circulating plasma virus, especially in prevalent cases late in infection, depending on the duration of the immunocompetent period (Lukashov et al., 1995) . Our data show that regardless of the compartment, each consensus sequence (plasma and provirus) is identical to the Abidjan consensus sequence generated from the sample collection overall, including three populations in Abidjan, Côte d'Ivoire: female sex workers (FSW), tuberculosis patients (TB), and persons starting antiretroviral therapy. Recognizing that our data represent a snapshot of the virus population in each person, and that the rate of HIV-1 intrahost evolution may be a function of the host selective forces acting on the replicating virus (Delwart et al., 1997) , we did not compare intrahost provirus and RNA since the consensus sequence was identical for all interhost viral compartments. Our data also show that regardless of its derivation, the consensus derived from these Ivorian strains is essentially homologous to CRF02-AG. The recombinant strain CRF02-AG or Abidjan consensus sequence based on the local strains may increase the chance for success in vaccinated persons within West Africa, assuming the vaccine is HIV-1 subtype-specific. Furthermore, Côte d'Ivoire may be a good place for a vaccine efficacy trial because the vaccine will be challenged by a limited diversity of strains.
Determining whether a vaccine will protect against diverse strains of HIV is critical. Although a vaccinee may have a diminished immune response to an unmatched HIV strain, a weaker response might still be sufficient to afford some level of protection. The importance of matching vaccine immunogens to circulating HIV strains will not be fully understood until results from vaccine trials in areas with multiple subtypes become available.
MATERIALS AND METHODS

Study samples
Samples for this study were collected from persons identified in three populations in Abidjan, Côte d'Ivoire: FSW, TB, and persons starting antiretroviral therapy. Informed consent was obtained from all study participants under a protocol approved by CDC and local Internal Review Boards. Four FSWs (incident cases) were included from a group of HIV-seronegative FSWs that Project Retro CI was following in a microbicide clinical trial initiated in 1994 at a confidential clinic in Abidjan. Incident cases were determined by seroconversion to HIV within 12 weeks of last negative blood sample. Four samples were collected from TB patients who were participating in an HIV counseling and testing service that was made available in 1994 at all TB treatment centers in Côte d'Ivoire. Fifteen samples were collected from persons seeking care in the UNAIDS Drug Access Initiative (UNAIDS DAI) which was initiated in 1998. The 19 prevalent cases were selected from TB patients and persons beginning antiretroviral therapy in the UNAIDS DAI with CD4 counts Ͼ500 per microliter. Blood samples for lymphocyte separation were collected from the study participants. Specimens were tested for antibodies to HIV-1/2 as described previously .
Genetic subtyping
HIV-1-specific polymerase chain reaction (PCR) was done on uncultured peripheral blood mononuclear cells (PBMCs). Reverse transcriptase (RT)-PCR followed by DNA PCR was done on HIV-1 RNA recovered from plasma. The conditions for nested PCR and primer sets for PCR amplification of protease (297 bp) and gag p24 (444 bp) have been described elsewhere (Janini et al., 1996; Brennan et al., 1997) . The standard primer for gag p24 gene RT-PCR amplification was P2470R (5Ј CCC TGR CAT GCT GTC ATC A). Thermal cycling conditions for RT-PCR were: 42°C, 15 min; 99°C, 5 min; and 4°C, 5 min.
DNA sequencing was completed using the ABI Prism dye terminator cycle sequencing reaction kit (PerkinElmer, Foster, CA) with Amplitaq DNA polymerase FS and automated sequencer ABI Model 373 (Applied Biosystems, Foster City, CA). HIV-1 sequences were derived from the HIV gag p24 and pol protease regions. Both strands of the PCR products were sequenced directly. Sequence data were analyzed using Sequencher 3.0 software (Gene Codes, Ann Arbor, MI). Nucleic acid sequences were trimmed to equivalent lengths and aligned with representative HIV-1 group M subtypes and multiple CRF02-AG strains available in the Los Alamos database. The neighbor-joining method included in the Phylip 3.5c software package (Courtesy of Joe Felsenstein, University of Washington, Seattle, WA) was used to construct the phylogenetic trees.
